Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cell and gene therapy

- PMLiVE

Oxford Biomedica gets £53m cash injection from Novo venture arm

Cell and gene therapy specialist needs to invest to stay ahead

- PMLiVE

Novartis secures US approval – and payers’ blessing – for $2m gene therapy Zolgensma

Novel financing deal could be sector's future

- PMLiVE

European elections: Eurosceptics and Greens rise, but big parties hold on

Horse-trading over top jobs now begins

- PMLiVE

As Europe goes to polls, pharma seeks to keep healthcare, R&D a priority

Eurosceptics want to block greater EU integration

- PMLiVE

No deal or revoke looming as fourth vote on Brexit nears

Voters set to protest via EU elections, no-deal remains possibility

- PMLiVE

Health comms agency emotive hires new cell and gene therapy leader

New division will cater to fast-expanding field

- PMLiVE

Europe responding to gene therapy challenge, but picture remains fragmented

Germany, Italy and England using outcomes-based deals

- PMLiVE

Syncona launches another cell therapy company, Treg specialist Quell

Focuses on novel immune system approach

- PMLiVE

Bluebird and Alexion veterans launch cell and gene venture ElevateBio

'Basecamp' will provide expertise and labs to launch multiple firms

- PMLiVE

Brexit “having impact on EU drug development”

EMA and UK regulator both affected

- PMLiVE

Gilead unveils plan to separate Kite cell therapy unit

Comes as Yescarta misses analyst expectations

- PMLiVE

European approval for Skyrizi, hot on the heels of US

Welcome news, but can't replace $20bn Humira

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links